Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
KalVista Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing oral plasma kallikrein inhibitors for hereditary angioedema (HAE) and diabetic macular edema (DME). The company's lead asset, sebetralstat, is in Phase 3 trials for on-demand HAE treatment, targeting a rare disease market with limited oral therapy options and high unmet need among approximately 10,000-15,000 diagnosed HAE patients in the US.
KalVista operates a classic biotech development model: invest in R&D to advance oral plasma kallikrein inhibitors through clinical trials, obtain regulatory approval, then commercialize directly or via partnerships. The HAE market commands premium pricing ($300,000-500,000 annual treatment costs) due to rare disease status, orphan drug designation benefits, and limited competition. Sebetralstat targets on-demand HAE attack treatment, competing against injectable therapies (Takeda's Firazyr, CSL's Berinert) with differentiation through oral convenience. Pricing power stems from orphan drug economics, payer willingness for rare diseases, and potential superiority to existing oral prophylaxis options.
Phase 3 KONFIDENT trial data readouts for sebetralstat in on-demand HAE treatment (primary endpoint: time to symptom relief)
FDA regulatory milestones including NDA submission timing and approval decisions (orphan drug 6-month review)
Clinical trial enrollment rates and timeline updates for HAE and DME programs
Cash runway extensions through equity raises, partnerships, or non-dilutive financing
Competitive developments from Takeda, BioCryst, Ionis, or Pharvaris in HAE space
Binary clinical trial risk: Phase 3 KONFIDENT failure would eliminate primary value driver and likely trigger 60-80% stock decline given single-asset focus
Regulatory approval uncertainty: FDA may require additional trials, safety data, or impose restrictive labeling limiting commercial potential
Reimbursement risk: Payer pushback on pricing or restrictive coverage policies could limit market penetration despite orphan status
Competitive displacement: Oral HAE prophylaxis drugs (BioCryst's Orladeyo) or superior on-demand therapies could erode sebetralstat market opportunity
Takeda dominates HAE market with established injectable therapies and strong KOL relationships; difficult to displace incumbent despite oral advantage
BioCryst's Orladeyo (oral prophylaxis) approved 2020 creates treatment paradigm shift that may reduce on-demand therapy demand
Pipeline competition from Pharvaris (oral prophylaxis), Ionis (antisense), and Intellia (CRISPR gene editing) targeting same patient population
Large pharma acquisition risk: competitors could acquire emerging HAE assets, consolidating market and limiting partnership opportunities
High cash burn ($60-80M annually) with $200M+ cash position implies 2.5-3 year runway; requires equity raise before commercialization
Debt/Equity ratio of 8.80 indicates significant leverage, likely convertible notes creating dilution risk upon conversion
Negative ROE (-282%) and ROA (-61.9%) reflect pre-revenue status; equity raises at depressed valuations highly dilutive to existing shareholders
Current ratio of 7.22 provides near-term liquidity cushion but masks structural funding gap to reach profitability
low - Clinical-stage biotech valuations driven primarily by binary clinical/regulatory events rather than economic cycles. Rare disease drug demand is non-discretionary and insulated from GDP fluctuations. However, capital markets access for funding is cyclical: risk-off environments compress biotech valuations and impair equity financing ability, creating liquidity risk for cash-burning development companies.
Rising rates negatively impact valuation through higher discount rates applied to distant future cash flows (sebetralstat revenue potentially 2028+). Clinical-stage biotechs are long-duration assets with no near-term earnings, making them particularly sensitive to risk-free rate changes. Higher rates also increase competition from fixed income, reducing speculative capital flows into high-risk biotech. Financing costs rise if debt is utilized, though KalVista primarily equity-funded.
Minimal direct credit exposure as pre-revenue company with no customer receivables or credit-dependent sales. However, credit market conditions affect: (1) ability to raise capital through convertible debt offerings, (2) venture debt availability for non-dilutive financing, and (3) broader biotech sector sentiment as credit spreads correlate with risk appetite for speculative growth assets.
growth - High-risk, high-reward clinical-stage biotech attracts speculative growth investors and biotech-focused hedge funds willing to underwrite binary event risk. Typical holders include specialist healthcare funds, venture capital crossover investors, and retail momentum traders. Not suitable for value or income investors given no earnings, dividends, or tangible book value. Investment thesis predicated on 5-10x return potential if sebetralstat achieves approval, offset by total loss risk on clinical failure.
high - Clinical-stage biotechs exhibit extreme volatility with 50-80% single-day moves common on trial data releases. Implied volatility typically 80-120% ahead of binary events. Low float and institutional concentration amplify price swings. Stock highly correlated with biotech sector beta but idiosyncratic clinical risk dominates. Recent 44.3% one-year return reflects positive clinical momentum, but historical drawdowns exceed 70% during setbacks.
